3 horrendous healthcare stocks this week   4-11-14
Upcoming SlideShare
Loading in...5

3 horrendous healthcare stocks this week 4-11-14



This week's worst healthcare stocks

This week's worst healthcare stocks



Total Views
Views on SlideShare
Embed Views



8 Embeds 2,426

http://www.fool.com 2394
http://m.fool.com 11
http://cms.fool.com 10
http://www.barchart.com 5
http://www.google.com 2
http://barchartjson.websol.barchart.com 2
http://www.mysanantonio.com 1
http://translate.googleusercontent.com 1


Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.


11 of 1

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-affymetrix-inc-shares-dropped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx

3 horrendous healthcare stocks this week   4-11-14 3 horrendous healthcare stocks this week 4-11-14 Presentation Transcript

  • 3 Horrendous Health-Care Stocks This Week
  • It’s been a horrible week for many health-care stocks. A few, though, had particularly bad rides. Here are the week’s most horrendous health-care stocks of all.
  • The biotech’s shares plunged over 28% for the week. Puma Biotechnology (NYSE: PBYI) Source: Yahoo! Finance
  • • Puma announced results from a mid- stage study of neratinib in treating breast cancer. • The results disappointed investors because the benefits weren’t as positive as hoped. • 39% of patients developed moderate to severe diarrhea, prompting Puma to add higher doses of an anti- diarrheal drug to other studies of neratinib. Why Puma’s shares got pummeled
  • Shares of the biopharmaceutical company focusing on pet medications dropped nearly 23% this week. Kindred Biosciences (NasdaqOTH: KIN) Source: Yahoo! Finance
  • • Kindred announced a secondary offering of 3.45 million shares at $18 on Tuesday with little effect on the stock price. • The company presented at the Needham conference on Wednesday – again with shares not moving much. • Thursday saw a huge drop with the big overall biotech plunge. • The stock continued a steady sell-off that started over three weeks ago. Why Kindred shares crashed
  • The stock of the cloud-based healthcare technology company fell nearly 21% this week. Castlight Health (NYSE: CSLT) Source: Yahoo! Finance
  • • After a big IPO pop in March, Castlight has felt the sting of critics in recent weeks. • Castlight is the “most overpriced IPO of the century,” according to Yahoo! Finance. • The overall pullback in technology stocks seems to be sweeping Castlight in its path, but at an even faster rate of decline -- probably because of those perceptions that the stock is priced too highly. Why Castlight dimmed
  • • Any of this week’s horrendous stocks could rebound, but Puma Biotechnology gets the nod as most likely to bounce back. • The market reaction to Puma’s neratinib results seems somewhat overdone -- there’s still a good chance that the drug will perform well in phase 3 studies. • As investors digest the latest results more (and the general biotech sell-off ultimately wanes), Puma could mount a comeback. Best shot at bouncing back?
  • Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!